> Skip repeated content

APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking) International Clinical Database and Repository.

IRB Number: 2014-252

January 31, 2014

Institutional Review Board, Hospital for Special Surgery

The safety of our participants is our top priority. The trial/study is approved and periodically reviewed by the Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial or research study, the investigator will explain the purpose of the trial/study, its expected benefits, any possible risks or side effects, and what your role will be. If you want to join the trial/study, you must sign informed consent documents. You can leave a trial/study at any time without penalty.

For further information, see Understanding Clinical Trials/Research Studies.

Principal Investigator

Doruk Erkan, M.D


Jane E. Salmon, M.D.
Michael Lockshin, M.D.
JoAnn Vega
Glendalee Ramon


An international collaboration, entitled the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking ("APS ACTION") (www.apsaction.org), has created a web-based ‘Clinical Database and Repository”, which will function as:
(1) a database for better defining aPL-related clinical problems and
     treatment responses;
(2) a repository for standardizing aPL tests; and
(3) a resource for future basic science and clinical research projects. 


Inclusion/Exclusion Criteria

• Age 18-75
• Persistent (at least 12 weeks apart) aPL-positivity within 12 months prior to the entry defined as:
o aCL IgG/M/A (> 40U, medium-to-high titer, and/or greater than the 99th percentile) and/or
o aβ2GPI IgG/M/A (>40U, medium-to-high titer, and/or greater than the 99th percentile) and/or
o Positive LA test based on the International Society of Thrombosis & Haematosis Recommendations 

• Patient refusal
• Inability to comply with study and follow-up procedures

Contact Information

JoAnn Vega, Study Coordinator 
212. 774.2795